「to」の検索結果
426件:341~345件目を表示
-

xam Co., Ltd. (hereinafter “Rexxam”). 3in1 Smart is a compact all-in-one unit that integrates refractometry, keratometry, and tonometry into a single device, consolidating essential functions in a spa...
https://www.senju.co.jp/system/files/content_news/2026-05/ENG_20260601_0.pdf -

ミケランLA点眼液 添付文書 2022年3月改訂 TD75X2B17
-0.65 [-1.66, 0.34] ミケラン点眼液1% 75 -5.67±3.30 眼圧下降度:平均値±標準偏差、差:平均値 (症例数は点眼60日後の 症例数を示す。 ) ITT:Intent-to-treat 副作用発現頻度は、本剤1%で74例中2例 (2.7%) 、ミケラン 点眼液1%で75例中1例 (1.3%) であった。副作用は、本剤1% では点状角膜炎及び浮動性めまいが各1例 (1...
https://www.senju.co.jp/system/files/product_other_file/2022-03/MKLA_17_20220330_0.pdf -

, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has entered into a LicensingAgreement for Corneal Esthesiometer Brill in Japan with Brill International (Headquart...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -

Company Profile | About Senju | SENJU Pharmaceutical
512 FAX:+81-6-6226-0406 Date of Incorporation April 9, 1947 Capital 1,415,500,000 yen Board of Directors Chairman of the BoardYukoh Yoshida President & CEOShuhei Yoshida Chief Operating OfficerTakeshi...
http://www.senju.co.jp/english/about/outline.html -

Publications | Research & Development | SENJU Pharmaceutica
cebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease Tomoyuki Wada1, Kazunori Omatsu1, Stephen C. Pflugfelder2 1: Senju Pharmaceutical Co., Ltd, Hyogo, J...
http://www.senju.co.jp/english/rd/thesis/